drug approvals

FDA grants approval to Pralsetinib for NSCLC With RET Fusion Mutation

By Dr. Anish Shah Bronx-Lebanon Hospital   On August 9, 2023, the U.S. Food and Drug Administration granted regular approval…

1 year ago

FDA Approves Tucatinib Plus Trastuzumab for RAS Wild-type, HER2+ Metastatic Colorectal Cancer

On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients…

2 years ago